Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin levels ...

Rusfertide more than doubled the percentage of patients achieving a clinical response, defined as the absence of phlebotomy eligibility during study weeks 20-32 of the trial (76.9% vs 32.9% with ...

The VERIFY study demonstrated that treatment with rusfertide controls hematocrit levels in phlebotomy-dependent patients, including patients receiving cytoreductive therapies,” said Dr. Andrew T.

To meet phlebotomy eligibility, patients in the study were required to have: confirmed hematocrit ≥45% that was ≥3% higher than their baseline hematocrit value, or hematocrit ≥48%.

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the ...

This week, the album at No. 1 on the charts is one everyone saw coming: With the biggest streaming numbers of 2025 and strong sales to boot, Morgan Wallen's I'm the Problem is the chart-topper it ...

How To Read a Chart Focus Area What to Focus On : Why It Matters Chart Type-Candlestick -Line -Bar -Point & Figure -Renko Provides different levels of detail on price movement and trend clarity.

Background Critically ill patients receive frequent routine and recurring blood tests, some of which are unnecessary. Aim To reduce unnecessary routine phlebotomy in a 30-bed tertiary medical-surgical ...